|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Cost of goods sold | |||||
| Gross profit (loss) | |||||
| Research and development expenses | |||||
| Selling, general and administrative expenses | |||||
| Loss on write-down of assets held for sale | |||||
| Loss from impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense), net: | |||||
| Interest expense | |||||
| Remeasurement of warrant liability | |||||
| Remeasurement of derivative liability | |||||
| Gain on debt restructuring, net of exchange fees | |||||
| Other, net | |||||
| Total other income (expense), net | |||||
| Income (loss) before taxes | |||||
| Income tax (benefit) expense | |||||
| Equity in losses of unconsolidated joint venture | |||||
| Net income (loss) | |||||
| Less: Earnings allocated to participating securities | |||||
| Net income (loss) available to common stockholders—basic (in shares) | |||||
| Net income (loss) per share available to common stockholders—basic (in dollars per share) | |||||
| Weighted average common shares outstanding—Basic (in shares) | |||||
| Net loss per share available to common stockholders—diluted (in dollars per share) | |||||
| Weighted average common shares outstanding—diluted (in shares) |
Loading...